首页 > 最新文献

Bjog-An International Journal of Obstetrics and Gynaecology最新文献

英文 中文
Standardised Methods for Developing Conceptual Frameworks for Placental Disorders of Pregnancy: Pre-Eclampsia and Stillbirth.
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-19 DOI: 10.1111/1471-0528.18083
Terteel Elawad, Mai-Lei Woo Kinshella, Ellie Stokes, Kelly Pickerill, Elisa Dalle Piagge, Marianne Vidler, Ella Stanley, Marie-Laure Volvert, Jeffrey N Bone, Helen Elwell, Hiten D Mistry, Violet Mateljan, Eleni Tsigas, Veronique Filippi, Peter von Dadelszen, Hannah Blencowe, Laura A Magee

Background: Risk factors for the placental disorders of pregnancy (pre-eclampsia, fetal growth restriction, preterm birth, and stillbirth) are complex, frequently involving the interplay between clinical factors and wider social and environmental determinants of health. Biomarkers modulate the maternal and fetal responses to biological processes that underlie the development of placental disorders.

Objectives: To develop a standardised methodology to assess the importance of, and inter-relationships between, candidate risk factors for the various placental disorders.

Search strategy: Systematic searches were conducted using Medline, Embase, Health Technology Assessments, Database of Abstracts of Reviews of Effects, Cochrane Library databases, Google Scholar, and reference lists of retrieved papers.

Selection criteria: We deployed a hierarchy of reviews, systematic reviews, and cohort studies with at least 1000 participants (100 for biomarker studies), published in the prior decade.

Data collection and analysis: We assessed the strengths of association and quality of evidence linking risk factors with individual placental outcomes.

Conclusions: We have developed a standardised approach to assess the importance and inter-relatedness of putative risk factors for the placental disorders of pregnancy.

{"title":"Standardised Methods for Developing Conceptual Frameworks for Placental Disorders of Pregnancy: Pre-Eclampsia and Stillbirth.","authors":"Terteel Elawad, Mai-Lei Woo Kinshella, Ellie Stokes, Kelly Pickerill, Elisa Dalle Piagge, Marianne Vidler, Ella Stanley, Marie-Laure Volvert, Jeffrey N Bone, Helen Elwell, Hiten D Mistry, Violet Mateljan, Eleni Tsigas, Veronique Filippi, Peter von Dadelszen, Hannah Blencowe, Laura A Magee","doi":"10.1111/1471-0528.18083","DOIUrl":"https://doi.org/10.1111/1471-0528.18083","url":null,"abstract":"<p><strong>Background: </strong>Risk factors for the placental disorders of pregnancy (pre-eclampsia, fetal growth restriction, preterm birth, and stillbirth) are complex, frequently involving the interplay between clinical factors and wider social and environmental determinants of health. Biomarkers modulate the maternal and fetal responses to biological processes that underlie the development of placental disorders.</p><p><strong>Objectives: </strong>To develop a standardised methodology to assess the importance of, and inter-relationships between, candidate risk factors for the various placental disorders.</p><p><strong>Search strategy: </strong>Systematic searches were conducted using Medline, Embase, Health Technology Assessments, Database of Abstracts of Reviews of Effects, Cochrane Library databases, Google Scholar, and reference lists of retrieved papers.</p><p><strong>Selection criteria: </strong>We deployed a hierarchy of reviews, systematic reviews, and cohort studies with at least 1000 participants (100 for biomarker studies), published in the prior decade.</p><p><strong>Data collection and analysis: </strong>We assessed the strengths of association and quality of evidence linking risk factors with individual placental outcomes.</p><p><strong>Conclusions: </strong>We have developed a standardised approach to assess the importance and inter-relatedness of putative risk factors for the placental disorders of pregnancy.</p>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Need for Understanding Beliefs and Barriers Around Physical Activity Postpartum Among South Asian Immigrant Women to Improve Health Equity: A Commentary.
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-19 DOI: 10.1111/1471-0528.18121
I A Lesser, B Mahmood, S A Lear, C Bean
{"title":"The Need for Understanding Beliefs and Barriers Around Physical Activity Postpartum Among South Asian Immigrant Women to Improve Health Equity: A Commentary.","authors":"I A Lesser, B Mahmood, S A Lear, C Bean","doi":"10.1111/1471-0528.18121","DOIUrl":"https://doi.org/10.1111/1471-0528.18121","url":null,"abstract":"","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Towards the Development of a Conceptual Framework of the Determinants of Pre-Eclampsia: A Hierarchical Systematic Review of Social Determinants.
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-19 DOI: 10.1111/1471-0528.18082
Mai-Lei Woo Kinshella, Kelly Pickerill, Sarina Prasad, Olivia Campbell, Jalila Devji, Lívia Vieira Lopes, Rosa Balleny, Terteel Elawad, Rachel Craik, Marie-Laure Volvert, Hiten D Mistry, Hannah Blencowe, Véronique Filippi, Peter von Dadelszen, Laura A Magee, Marianne Vidler

Background: Existing reviews of pre-eclampsia determinants have focused on clinical and genetic risk factors.

Objective: To evaluate social determinants for pre-eclampsia prevention.

Search strategy: Systematic searches were conducted from relevant electronic databases from inception of each database to 30th December 2024.

Selection criteria: Reviews and large cohort studies (≥ 1000 participants), published between 2013 and 2024, reporting quantitative associations between social determinant exposures and pre-eclampsia outcomes.

Data collection and analysis: Titles and abstracts, then relevant full-texts were reviewed by two reviewers, independently. Strength of association was evaluated as 'definite' (odds ratios [OR] or relative risk [RR] ≥ 3.00 or < 0.33), 'probable' (OR or RR 1.50-2.99 or 0.33-0.67), 'possible' (OR or RR 1.10-1.49 or 0.68-0.89), or 'unlikely' (OR or RR 0.90-1.09). Quality of the evidence was high, moderate, low, or very-low, using GRADE.

Main results: Twenty-seven publications found 24 associations of pre-eclampsia with socioeconomic status, social support/exclusion, healthcare access, and occupational and physical environmental factors. One association (polygamy) was definite (low-quality evidence). Probable associations included: work stress, lack of antenatal care and heat exposure in early pregnancy (high-quality evidence); prolonged occupational exposure to whole body vibrations or bending, distance to health facility, and UV-B radiation exposure (protective factor), all based on moderate-quality evidence; and neighbourhood deprivation, rotating work shifts, and Asian/Oceanian origins (protective factor), all based on low-quality evidence. There were 13 possible associations, which did not include education.

Conclusion: Our findings support recommendations to address climate change, strengthen occupational protection, and promote early antenatal attendance. Social determinants may be indicative of upstream factors (e.g., obesity) that increase likelihood of clinical risk factors for pre-eclampsia incidence and severity.

{"title":"Towards the Development of a Conceptual Framework of the Determinants of Pre-Eclampsia: A Hierarchical Systematic Review of Social Determinants.","authors":"Mai-Lei Woo Kinshella, Kelly Pickerill, Sarina Prasad, Olivia Campbell, Jalila Devji, Lívia Vieira Lopes, Rosa Balleny, Terteel Elawad, Rachel Craik, Marie-Laure Volvert, Hiten D Mistry, Hannah Blencowe, Véronique Filippi, Peter von Dadelszen, Laura A Magee, Marianne Vidler","doi":"10.1111/1471-0528.18082","DOIUrl":"https://doi.org/10.1111/1471-0528.18082","url":null,"abstract":"<p><strong>Background: </strong>Existing reviews of pre-eclampsia determinants have focused on clinical and genetic risk factors.</p><p><strong>Objective: </strong>To evaluate social determinants for pre-eclampsia prevention.</p><p><strong>Search strategy: </strong>Systematic searches were conducted from relevant electronic databases from inception of each database to 30th December 2024.</p><p><strong>Selection criteria: </strong>Reviews and large cohort studies (≥ 1000 participants), published between 2013 and 2024, reporting quantitative associations between social determinant exposures and pre-eclampsia outcomes.</p><p><strong>Data collection and analysis: </strong>Titles and abstracts, then relevant full-texts were reviewed by two reviewers, independently. Strength of association was evaluated as 'definite' (odds ratios [OR] or relative risk [RR] ≥ 3.00 or < 0.33), 'probable' (OR or RR 1.50-2.99 or 0.33-0.67), 'possible' (OR or RR 1.10-1.49 or 0.68-0.89), or 'unlikely' (OR or RR 0.90-1.09). Quality of the evidence was high, moderate, low, or very-low, using GRADE.</p><p><strong>Main results: </strong>Twenty-seven publications found 24 associations of pre-eclampsia with socioeconomic status, social support/exclusion, healthcare access, and occupational and physical environmental factors. One association (polygamy) was definite (low-quality evidence). Probable associations included: work stress, lack of antenatal care and heat exposure in early pregnancy (high-quality evidence); prolonged occupational exposure to whole body vibrations or bending, distance to health facility, and UV-B radiation exposure (protective factor), all based on moderate-quality evidence; and neighbourhood deprivation, rotating work shifts, and Asian/Oceanian origins (protective factor), all based on low-quality evidence. There were 13 possible associations, which did not include education.</p><p><strong>Conclusion: </strong>Our findings support recommendations to address climate change, strengthen occupational protection, and promote early antenatal attendance. Social determinants may be indicative of upstream factors (e.g., obesity) that increase likelihood of clinical risk factors for pre-eclampsia incidence and severity.</p>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Monochorionic Twin Pregnancy Green-Top Guideline No. 51 (2024 Partial Update).
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-18 DOI: 10.1111/1471-0528.18055
Mark D Kilby, Leanne Bricker
{"title":"Management of Monochorionic Twin Pregnancy Green-Top Guideline No. 51 (2024 Partial Update).","authors":"Mark D Kilby, Leanne Bricker","doi":"10.1111/1471-0528.18055","DOIUrl":"https://doi.org/10.1111/1471-0528.18055","url":null,"abstract":"","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility of a Standardised Mid-Trimester Ultrasound Protocol: A National Multicenter Study.
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-13 DOI: 10.1111/1471-0528.18102
Thierry Bultez, Laurent Julien Salomon, Houman Mahallati, Nicolas Fries

Objective: Evaluate the feasibility and quality of a national standardised mid-trimester ultrasound protocol using a consensus-based quality assessment (QA) scoring system.

Design: Multicenter prospective observational 'FLASH' study.

Setting: (i) Assessing the feasibility of a standardised protocol of 24 views at the mid-trimester scan, with 21 recommended and 3 additional views, in routine practice. (ii) Assessing the quality of these images by evaluating the presence of conformity criteria. (iii) Analysing the reliability between self-assessment and peer-assessment of the images.

Population: A total of 440 mid-trimester scans.

Methods: A consensus-based QA scoring system comprising 73 conformity criteria was established with 28 experts using a 3-round Delphi method. Secondly, we asked operators to record 5 consecutive routine mid-trimester scans. Images were analysed by the sonographer themselves and by a qualified expert according to the scoring system. The frequency of recorded images was calculated for each of the views. Factors associated with missing images per scan were evaluated. The robustness of conformity criteria was assessed by reliability between self-evaluation and peer-evaluation.

Main outcome measures: Based on 9849 images, we observed feasibility of the 21 recommended standardised views for mid-trimester scan ranging from 88.5% to 100%.

Results: Most conformity criteria (64/73, 88%) were met in over 90% of cases. Gwet's AC1 correlation between expert evaluation (peer-evaluation) and participant evaluation (self-evaluation) was greater than 0.80 for 70/73 (96%) criteria.

Conclusion: This large-scale 2-month 'flash' observational study demonstrates the feasibility and quality of a national standardised mid-trimester ultrasound protocol using a consensus-based QA scoring system.

{"title":"Feasibility of a Standardised Mid-Trimester Ultrasound Protocol: A National Multicenter Study.","authors":"Thierry Bultez, Laurent Julien Salomon, Houman Mahallati, Nicolas Fries","doi":"10.1111/1471-0528.18102","DOIUrl":"https://doi.org/10.1111/1471-0528.18102","url":null,"abstract":"<p><strong>Objective: </strong>Evaluate the feasibility and quality of a national standardised mid-trimester ultrasound protocol using a consensus-based quality assessment (QA) scoring system.</p><p><strong>Design: </strong>Multicenter prospective observational 'FLASH' study.</p><p><strong>Setting: </strong>(i) Assessing the feasibility of a standardised protocol of 24 views at the mid-trimester scan, with 21 recommended and 3 additional views, in routine practice. (ii) Assessing the quality of these images by evaluating the presence of conformity criteria. (iii) Analysing the reliability between self-assessment and peer-assessment of the images.</p><p><strong>Population: </strong>A total of 440 mid-trimester scans.</p><p><strong>Methods: </strong>A consensus-based QA scoring system comprising 73 conformity criteria was established with 28 experts using a 3-round Delphi method. Secondly, we asked operators to record 5 consecutive routine mid-trimester scans. Images were analysed by the sonographer themselves and by a qualified expert according to the scoring system. The frequency of recorded images was calculated for each of the views. Factors associated with missing images per scan were evaluated. The robustness of conformity criteria was assessed by reliability between self-evaluation and peer-evaluation.</p><p><strong>Main outcome measures: </strong>Based on 9849 images, we observed feasibility of the 21 recommended standardised views for mid-trimester scan ranging from 88.5% to 100%.</p><p><strong>Results: </strong>Most conformity criteria (64/73, 88%) were met in over 90% of cases. Gwet's AC1 correlation between expert evaluation (peer-evaluation) and participant evaluation (self-evaluation) was greater than 0.80 for 70/73 (96%) criteria.</p><p><strong>Conclusion: </strong>This large-scale 2-month 'flash' observational study demonstrates the feasibility and quality of a national standardised mid-trimester ultrasound protocol using a consensus-based QA scoring system.</p>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "The Hayman Technique: A Simple Method to Treat Postpartum Haemorrhage".
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-13 DOI: 10.1111/1471-0528.18099
{"title":"Correction to \"The Hayman Technique: A Simple Method to Treat Postpartum Haemorrhage\".","authors":"","doi":"10.1111/1471-0528.18099","DOIUrl":"https://doi.org/10.1111/1471-0528.18099","url":null,"abstract":"","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regarding the Association Between Polycystic Ovary Syndrome and Risk of Pre-Eclampsia.
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-13 DOI: 10.1111/1471-0528.18087
Hong Li, Jue He, Yan Xu, Minhui Yi, Yan Qin
{"title":"Regarding the Association Between Polycystic Ovary Syndrome and Risk of Pre-Eclampsia.","authors":"Hong Li, Jue He, Yan Xu, Minhui Yi, Yan Qin","doi":"10.1111/1471-0528.18087","DOIUrl":"https://doi.org/10.1111/1471-0528.18087","url":null,"abstract":"","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimising Aspirin Use for Pre-Eclampsia Prevention: The Critical Role of Dose, Timing and Adherence
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-11 DOI: 10.1111/1471-0528.18095
Bethany Atkins, Dimitrios Siassakos
<p>There is abundant evidence that aspirin, commenced at 12 weeks gestation, can be very effective in preventing pre-eclampsia, including preterm pre-eclampsia, preterm delivery and severe pre-eclampsia variants such as HELLP syndrome. However, some clinicians may consider it only modestly effective and neglect its use. Thus, attempts to reduce the morbidity and mortality associated with pre-eclampsia may focus instead on managing its complications, and developing new diagnostics and drugs. Aspirin is hypothesised to improve placental development, either preventing entirely or delaying onset of pre-eclampsia.</p><p>The Cochrane review by Duley et al. [<span>1</span>] describes a ‘small-to-moderate’ benefit of aspirin in preventing pre-eclampsia, preterm birth, small-for-gestational age and perinatal death. However, of 34 514 women with individual patient data available, only 9272 were randomised before 16 weeks gestation, and only 5070 received > 75 mg per day. Does the amalgamation of low- and high-doses, with early and late commencement of aspirin give the appearance of lower efficacy, and dissuade clinicians from prioritising aspirin?</p><p>In resource-limited contexts, where the likelihood of healthy survival to adulthood is significantly lower for preterm infants [<span>2</span>], the importance of a safe, low-cost intervention such as aspirin is even more important. Underestimation of low-cost, effective interventions such as aspirin may cause considerable harm [<span>2</span>].</p><p>This editorial seeks to review the impact of dosage, timing and adherence to aspirin on its efficacy in pre-eclampsia prevention, and explore special considerations for utilisation.</p><p>The Cochrane review [<span>1</span>] examined aspirin dosage. Examining studies with individual patient data available, there appeared to be a greater reduction in risk of pre-eclampsia in the minority of women allocated ≥ 75 mg aspirin than those allocated < 75 mg aspirin (9107 women, 16 trials; RR 0.78, 95% CI 0.66–0.92 vs. 22 618 women, 11 trials; RR 0.92, 95% CI 0.85–1.00). The review found no evidence of a difference by aspirin dose in foetal or neonatal death, preterm delivery or small-for-gestational age birth weight, but of the large studies [<span>3</span>] (ASPRE [<span>3</span>], BLASP 1998 [<span>4</span>], ERASME 2003 [<span>5</span>]) examining aspirin ≥ 75 mg, 61% of participants had poor adherence, and 40% commenced aspirin after 20 weeks.</p><p>Two systematic reviews investigated aspirin for prevention of pre-eclampsia and foetal growth restriction [<span>6</span>] (Roberge et al. 2016), and pre-term pre-eclampsia [<span>7</span>] (Roberge et al. 2018) respectively. The first [<span>6</span>] clearly demonstrated that aspirin commenced before 16 weeks reduced risk of pre-eclampsia (RR 0.57, 95% CI 0.43–0.75), severe pre-eclampsia (RR 0.47, 95% CI 0.26–0.83) and foetal growth restriction (RR 0.56, 95% CI 0.44–0.70). This was strongly dose-dependent. When
{"title":"Optimising Aspirin Use for Pre-Eclampsia Prevention: The Critical Role of Dose, Timing and Adherence","authors":"Bethany Atkins,&nbsp;Dimitrios Siassakos","doi":"10.1111/1471-0528.18095","DOIUrl":"10.1111/1471-0528.18095","url":null,"abstract":"&lt;p&gt;There is abundant evidence that aspirin, commenced at 12 weeks gestation, can be very effective in preventing pre-eclampsia, including preterm pre-eclampsia, preterm delivery and severe pre-eclampsia variants such as HELLP syndrome. However, some clinicians may consider it only modestly effective and neglect its use. Thus, attempts to reduce the morbidity and mortality associated with pre-eclampsia may focus instead on managing its complications, and developing new diagnostics and drugs. Aspirin is hypothesised to improve placental development, either preventing entirely or delaying onset of pre-eclampsia.&lt;/p&gt;&lt;p&gt;The Cochrane review by Duley et al. [&lt;span&gt;1&lt;/span&gt;] describes a ‘small-to-moderate’ benefit of aspirin in preventing pre-eclampsia, preterm birth, small-for-gestational age and perinatal death. However, of 34 514 women with individual patient data available, only 9272 were randomised before 16 weeks gestation, and only 5070 received &gt; 75 mg per day. Does the amalgamation of low- and high-doses, with early and late commencement of aspirin give the appearance of lower efficacy, and dissuade clinicians from prioritising aspirin?&lt;/p&gt;&lt;p&gt;In resource-limited contexts, where the likelihood of healthy survival to adulthood is significantly lower for preterm infants [&lt;span&gt;2&lt;/span&gt;], the importance of a safe, low-cost intervention such as aspirin is even more important. Underestimation of low-cost, effective interventions such as aspirin may cause considerable harm [&lt;span&gt;2&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;This editorial seeks to review the impact of dosage, timing and adherence to aspirin on its efficacy in pre-eclampsia prevention, and explore special considerations for utilisation.&lt;/p&gt;&lt;p&gt;The Cochrane review [&lt;span&gt;1&lt;/span&gt;] examined aspirin dosage. Examining studies with individual patient data available, there appeared to be a greater reduction in risk of pre-eclampsia in the minority of women allocated ≥ 75 mg aspirin than those allocated &lt; 75 mg aspirin (9107 women, 16 trials; RR 0.78, 95% CI 0.66–0.92 vs. 22 618 women, 11 trials; RR 0.92, 95% CI 0.85–1.00). The review found no evidence of a difference by aspirin dose in foetal or neonatal death, preterm delivery or small-for-gestational age birth weight, but of the large studies [&lt;span&gt;3&lt;/span&gt;] (ASPRE [&lt;span&gt;3&lt;/span&gt;], BLASP 1998 [&lt;span&gt;4&lt;/span&gt;], ERASME 2003 [&lt;span&gt;5&lt;/span&gt;]) examining aspirin ≥ 75 mg, 61% of participants had poor adherence, and 40% commenced aspirin after 20 weeks.&lt;/p&gt;&lt;p&gt;Two systematic reviews investigated aspirin for prevention of pre-eclampsia and foetal growth restriction [&lt;span&gt;6&lt;/span&gt;] (Roberge et al. 2016), and pre-term pre-eclampsia [&lt;span&gt;7&lt;/span&gt;] (Roberge et al. 2018) respectively. The first [&lt;span&gt;6&lt;/span&gt;] clearly demonstrated that aspirin commenced before 16 weeks reduced risk of pre-eclampsia (RR 0.57, 95% CI 0.43–0.75), severe pre-eclampsia (RR 0.47, 95% CI 0.26–0.83) and foetal growth restriction (RR 0.56, 95% CI 0.44–0.70). This was strongly dose-dependent. When","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 5","pages":"547-551"},"PeriodicalIF":4.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.18095","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143385811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reproductive Implications and Management of Congenital Uterine Anomalies (2024 Second Edition)
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-06 DOI: 10.1111/1471-0528.18054
M. A. Akhtar, S. H. Saravelos, T. C. Li, K. Jayaprakasan, the Royal College of Obstetricians and Gynaecologists

Congenital uterine anomalies (CUAs) are malformations of the uterus (womb) that develop during fetal life. When a female baby is in her mother's uterus, her uterus develops as two separate halves from two tubular structures called Müllerian ducts, which fuse together before she is born. Anomalies that occur during the baby's development can be variable, from complete absence of the uterus through to more subtle anomalies, which are classified into specific categories. While conventional ultrasound is good at detecting CUAs, 3D ultrasound is used to confirm a diagnosis. If a complex uterine anomaly is suspected, additional investigations may be used, including MRI scanning, laparoscopy (where a camera is inserted into the cavity of the abdomen) and/or hysteroscopy (where a camera is placed in the uterine cavity). As there can be a link between CUAs and anomalies of the kidney and bladder, scans of these organs are also usually requested.

Although CUAs are present at birth, adult women typically do not have any symptoms, although some may experience painful periods. Most cases of CUA do not cause difficulties in becoming pregnant, and the outcome of pregnancy, in most cases, is good. However, these uterine anomalies are often discovered during investigations for infertility or miscarriage. Moreover, depending upon the type and severity of CUA, there may be increased risk of first and second trimester miscarriages, preterm birth, fetal growth restriction (smaller and lighter babies for the stage of pregnancy), pre-eclampsia (development of high blood pressure and protein in urine after the 20th week of pregnancy) and fetal malpresentation (baby not facing head-first down the birth canal) at birth. Surgical treatment may be considered for those who have had recurrent miscarriages and have a septate uterus, i.e. the uterine cavity is divided by a partition. In this case, surgery may reduce the chances of miscarriage. However, women should be informed that there is inconclusive and conflicting evidence regarding the improved likelihood of live births in this context. Further evidence from large randomised controlled trials are required to provide conclusive evidence-based recommendations for surgical treatment for septate uterus. Surgical treatment for other types of CUAs is not usually recommended as the risks outweigh potential benefits, and evidence for any benefits is lacking. Women with CUAs may be at an increased risk of preterm birth even after surgical treatment for a septate uterus. These people, if suspected to be at an increased risk of preterm birth based on the severity of CUA, should be followed up using an appropriate protocol for preterm birth as outlined in UK Preterm Birth Clinical Network Guidance.

{"title":"Reproductive Implications and Management of Congenital Uterine Anomalies (2024 Second Edition)","authors":"M. A. Akhtar,&nbsp;S. H. Saravelos,&nbsp;T. C. Li,&nbsp;K. Jayaprakasan,&nbsp;the Royal College of Obstetricians and Gynaecologists","doi":"10.1111/1471-0528.18054","DOIUrl":"10.1111/1471-0528.18054","url":null,"abstract":"<p>Congenital uterine anomalies (CUAs) are malformations of the uterus (womb) that develop during fetal life. When a female baby is in her mother's uterus, her uterus develops as two separate halves from two tubular structures called Müllerian ducts, which fuse together before she is born. Anomalies that occur during the baby's development can be variable, from complete absence of the uterus through to more subtle anomalies, which are classified into specific categories. While conventional ultrasound is good at detecting CUAs, 3D ultrasound is used to confirm a diagnosis. If a complex uterine anomaly is suspected, additional investigations may be used, including MRI scanning, laparoscopy (where a camera is inserted into the cavity of the abdomen) and/or hysteroscopy (where a camera is placed in the uterine cavity). As there can be a link between CUAs and anomalies of the kidney and bladder, scans of these organs are also usually requested.</p><p>Although CUAs are present at birth, adult women typically do not have any symptoms, although some may experience painful periods. Most cases of CUA do not cause difficulties in becoming pregnant, and the outcome of pregnancy, in most cases, is good. However, these uterine anomalies are often discovered during investigations for infertility or miscarriage. Moreover, depending upon the type and severity of CUA, there may be increased risk of first and second trimester miscarriages, preterm birth, fetal growth restriction (smaller and lighter babies for the stage of pregnancy), pre-eclampsia (development of high blood pressure and protein in urine after the 20th week of pregnancy) and fetal malpresentation (baby not facing head-first down the birth canal) at birth. Surgical treatment may be considered for those who have had recurrent miscarriages and have a septate uterus, i.e. the uterine cavity is divided by a partition. In this case, surgery may reduce the chances of miscarriage. However, women should be informed that there is inconclusive and conflicting evidence regarding the improved likelihood of live births in this context. Further evidence from large randomised controlled trials are required to provide conclusive evidence-based recommendations for surgical treatment for septate uterus. Surgical treatment for other types of CUAs is not usually recommended as the risks outweigh potential benefits, and evidence for any benefits is lacking. Women with CUAs may be at an increased risk of preterm birth even after surgical treatment for a septate uterus. These people, if suspected to be at an increased risk of preterm birth based on the severity of CUA, should be followed up using an appropriate protocol for preterm birth as outlined in UK Preterm Birth Clinical Network Guidance.</p>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 5","pages":"e86-e97"},"PeriodicalIF":4.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.18054","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143258754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Effectiveness of Assisted Oocyte Activation in ICSI: Pairwise Meta-Analyses and Systematic Evidence Evaluation.
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-01-30 DOI: 10.1111/1471-0528.18085
Mohamed Fawzy, Mohamad AlaaEldein Elsuity, Yasmin Magdi, Mosab Mahmod Rashwan, Mostafa Ali Gad, Nehal Adel, Mai Emad, Dina Ibrahem, Sara El-Gezeiry, Ahmed Etman, Niveen Shaker Ahmed, Tamer Abdelhamed, Ahmed El-Damen, Ali Mahran, Gamal I Serour, Mohamed Y Soliman

Background: Artificial oocyte activation (AOA) is used to improve fertilisation rates in intracytoplasmic sperm injection (ICSI) cycles.

Objectives: To assess the effectiveness of AOA on fertilisation, embryo development, and clinical outcomes, including live birth.

Search strategy: We searched PubMed, Cochrane, and Scopus from January 1990 to March 2024 using terms related to 'artificial oocyte activation' and 'ICSI.'

Selection criteria: Study designs included randomised trials (RCTs), quasi-experimental, cohort, and case-control studies that evaluated AOA's effects on ICSI outcomes, provided quantitative data and were published in English.

Data collection and analysis: Reviewers independently performed data extraction using a standardised form. Study quality was appraised using Joanna Briggs Institute (JBI) Checklists. Meta-analyses employed a random-effects model, and evidence was classified using a comprehensive numerical framework.

Main results: We included 45 studies covering 56 787 mature oocytes, 7463 women for clinical pregnancies, and 7063 women for live births. AOA showed potential in increasing fertilisation rates in patients with a history of low or absent fertilisation but did not enhance embryo development or clinical outcomes. This effect diminished when excluding low-quality studies or focusing solely on RCTs. In other patient groups, AOA showed limited or nonsignificant benefits.

Conclusions: Applying comprehensive evidence assessment, AOA showed potential in improving fertilisation rates in patients with fertilisation problems but no benefits for embryo development or live birth rates. This underscores the critical importance of rigorous evidence credibility in informing clinical practice in assisted conception.

{"title":"Evaluating the Effectiveness of Assisted Oocyte Activation in ICSI: Pairwise Meta-Analyses and Systematic Evidence Evaluation.","authors":"Mohamed Fawzy, Mohamad AlaaEldein Elsuity, Yasmin Magdi, Mosab Mahmod Rashwan, Mostafa Ali Gad, Nehal Adel, Mai Emad, Dina Ibrahem, Sara El-Gezeiry, Ahmed Etman, Niveen Shaker Ahmed, Tamer Abdelhamed, Ahmed El-Damen, Ali Mahran, Gamal I Serour, Mohamed Y Soliman","doi":"10.1111/1471-0528.18085","DOIUrl":"https://doi.org/10.1111/1471-0528.18085","url":null,"abstract":"<p><strong>Background: </strong>Artificial oocyte activation (AOA) is used to improve fertilisation rates in intracytoplasmic sperm injection (ICSI) cycles.</p><p><strong>Objectives: </strong>To assess the effectiveness of AOA on fertilisation, embryo development, and clinical outcomes, including live birth.</p><p><strong>Search strategy: </strong>We searched PubMed, Cochrane, and Scopus from January 1990 to March 2024 using terms related to 'artificial oocyte activation' and 'ICSI.'</p><p><strong>Selection criteria: </strong>Study designs included randomised trials (RCTs), quasi-experimental, cohort, and case-control studies that evaluated AOA's effects on ICSI outcomes, provided quantitative data and were published in English.</p><p><strong>Data collection and analysis: </strong>Reviewers independently performed data extraction using a standardised form. Study quality was appraised using Joanna Briggs Institute (JBI) Checklists. Meta-analyses employed a random-effects model, and evidence was classified using a comprehensive numerical framework.</p><p><strong>Main results: </strong>We included 45 studies covering 56 787 mature oocytes, 7463 women for clinical pregnancies, and 7063 women for live births. AOA showed potential in increasing fertilisation rates in patients with a history of low or absent fertilisation but did not enhance embryo development or clinical outcomes. This effect diminished when excluding low-quality studies or focusing solely on RCTs. In other patient groups, AOA showed limited or nonsignificant benefits.</p><p><strong>Conclusions: </strong>Applying comprehensive evidence assessment, AOA showed potential in improving fertilisation rates in patients with fertilisation problems but no benefits for embryo development or live birth rates. This underscores the critical importance of rigorous evidence credibility in informing clinical practice in assisted conception.</p>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Bjog-An International Journal of Obstetrics and Gynaecology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1